OPR - Delayed Quote • USD KURA Jul 2024 22.500 call (KURA240719C00022500) Follow 1.1500 0.0000 (0.00%) At close: April 19 at 3:01 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for KURA240719C00022500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: KURA Kura Oncology to Report First Quarter 2024 Financial Results Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML Kura Oncology to Participate in Stifel Targeted Oncology Forum Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript Q4 2023 Kura Oncology Inc Earnings Call Kura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial Results Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia Kura Oncology to Participate in Three Upcoming Investor Conferences Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
